Literature DB >> 28774752

Deciphering metabolic rewiring in breast cancer subtypes.

Martin P Ogrodzinski1, Jamie J Bernard2, Sophia Y Lunt3.   

Abstract

Metabolic reprogramming, an emerging hallmark of cancer, is observed in breast cancer. Breast cancer cells rewire their cellular metabolism to meet the demands of survival, proliferation, and invasion. However, breast cancer is a heterogeneous disease, and metabolic rewiring is not uniform. Each subtype of breast cancer displays distinct metabolic alterations. Here, we focus on unique metabolic reprogramming associated with subtypes of breast cancer, as well as common features. Therapeutic opportunities based on subtype-specific metabolic alterations are also discussed. Through this discussion, we aim to provide insight into subtype-specific metabolic rewiring and vulnerabilities that have the potential to better guide therapy and improve outcomes for patients.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28774752     DOI: 10.1016/j.trsl.2017.07.004

Source DB:  PubMed          Journal:  Transl Res        ISSN: 1878-1810            Impact factor:   7.012


  17 in total

Review 1.  A Comprehensive Review and Perspective on Anticancer Mechanisms of Withaferin A in Breast Cancer.

Authors:  Eun-Ryeong Hahm; Su-Hyeong Kim; Krishna B Singh; Kamayani Singh; Shivendra V Singh
Journal:  Cancer Prev Res (Phila)       Date:  2020-07-29

2.  Three dimensional engineered models to study hypoxia biology in breast cancer.

Authors:  Vaishali Aggarwal; Oshin Miranda; Paul A Johnston; Shilpa Sant
Journal:  Cancer Lett       Date:  2020-06-20       Impact factor: 8.679

3.  Alteration in lipid composition differentiates breast cancer tissues: a 1H HRMAS NMR metabolomic study.

Authors:  Anup Paul; Surendra Kumar; Anubhav Raj; Abhinav A Sonkar; Sudha Jain; Atin Singhai; Raja Roy
Journal:  Metabolomics       Date:  2018-09-03       Impact factor: 4.290

4.  Metabolomic profiling of mouse mammary tumor-derived cell lines reveals targeted therapy options for cancer subtypes.

Authors:  Martin P Ogrodzinski; Shao Thing Teoh; Sophia Y Lunt
Journal:  Cell Oncol (Dordr)       Date:  2020-07-20       Impact factor: 6.730

5.  FOXF2 differentially regulates expression of metabolic genes in non-cancerous and cancerous breast epithelial cells.

Authors:  Pang-Kuo Lo
Journal:  Trends Diabetes Metab       Date:  2018-07-06

Review 6.  Microbiome-Microbial Metabolome-Cancer Cell Interactions in Breast Cancer-Familiar, but Unexplored.

Authors:  Edit Mikó; Tünde Kovács; Éva Sebő; Judit Tóth; Tamás Csonka; Gyula Ujlaki; Adrienn Sipos; Judit Szabó; Gábor Méhes; Péter Bai
Journal:  Cells       Date:  2019-03-29       Impact factor: 6.600

7.  RNA-seq reveals novel cancer-selective and disease subtype-independent mechanistic targets of withaferin A in human breast cancer cells.

Authors:  Eun-Ryeong Hahm; Su-Hyeong Kim; Krishna B Singh; Shivendra V Singh
Journal:  Mol Carcinog       Date:  2020-11-04       Impact factor: 4.784

Review 8.  The Roles of p53 in Mitochondrial Dynamics and Cancer Metabolism: The Pendulum between Survival and Death in Breast Cancer?

Authors:  David E Moulder; Diana Hatoum; Enoch Tay; Yiguang Lin; Eileen M McGowan
Journal:  Cancers (Basel)       Date:  2018-06-08       Impact factor: 6.639

Review 9.  Mitochondrial Flexibility of Breast Cancers: A Growth Advantage and a Therapeutic Opportunity.

Authors:  Angelica Avagliano; Maria Rosaria Ruocco; Federica Aliotta; Immacolata Belviso; Antonello Accurso; Stefania Masone; Stefania Montagnani; Alessandro Arcucci
Journal:  Cells       Date:  2019-04-30       Impact factor: 6.600

10.  HDAC6 inhibitors sensitize non-mesenchymal triple-negative breast cancer cells to cysteine deprivation.

Authors:  Tahiyat Alothaim; Morgan Charbonneau; Xiaohu Tang
Journal:  Sci Rep       Date:  2021-05-26       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.